Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Bayer to Accumulate Medicoeconomic Evidence
June 20, 2011
- MediBIC: Glufosfamide Granted Orphan Drug Status in Europe
June 20, 2011
- Korosho to Preferentially Support High-Quality Clinical Research
June 20, 2011
- ASKA Spreading Risks in Production, Distribution to Ensure Stable Supplies
June 20, 2011
- Korosho Calls For Development of 3 Drugs Used Off-label
June 20, 2011
- Reform Council Sees ¥1.6 Tril. Increase in Healthcare/Nursing Expenditure in FY2015
June 20, 2011
- Top-3 Dispensing Pharmacy Chains Report Record-high Sales, Profits Driven by New Store Openings
June 20, 2011
- Infections Added as Serious ADE for Revlimid: Safety Info.
June 20, 2011
- Korosho's Expert Committee Proposes Creation of “Pediatric Cancer Hub Hospitals”
June 20, 2011
- Major Drugstore Chains Report Increased Sales in Dispensing Business
June 20, 2011
- Top-4 Generic Makers Report Double-digit Growth in Sales, Profits
June 20, 2011
- Korosho to Permit Telemarketing of OTC Drugs to Residents of Isolated Islands for 2 More Years
June 20, 2011
- Ain Pharmaciez Posts New Record-high Sales
June 20, 2011
- Sawai: Sales, Profits Up Driven by Good Sales to Pharmacies
June 20, 2011
- Takeda Launches Sonias Combination Tablet for Type 2 Diabetes
June 20, 2011
- Sales Down 5.8% for Ethical Drugs in April: Crecon Research & Consulting
June 20, 2011
- Towa: Double-digit Growth in Both Sales, Profits
June 20, 2011
- PAFSC Committee Turns Down Approval of Epogin for Anemia in Cancer Patients
June 20, 2011
- PMDA Should Develop Better Assessment Methods with Industry: Korosho Councilor Hirayama
June 20, 2011
- New Prescription of Actos Suspended in France, Germany due to Bladder Cancer Risk
June 20, 2011
ページ
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
As many as 47 new drug candidates are expected to win approval or secure NHI price listing in Japan in…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…